Phase 3 N=69,274 Rotavirus Efficacy and Safety Trial (REST)(V260-006)
Rotavirus Infections
Primary: Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo — 6; 5 Participants — p=0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=865 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: SLE Responder Index (SRI) Response Rate at Week 52 — 43.6; 51.4; 57.6 Percentage of participants — p=0.0006
Phase 3 N=1,473 MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Migraine Headache
Primary: Pain Relief at 2 Hours After the Initial Dose of Test Drug — 285; 322; 106; 172 Participants
Phase 3 N=2,694 Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Hypertension
Primary: Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) — -7.99; -13.98 mm Hg — p=<0.001
Phase 3 N=1,019 Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
Asthma
Primary: Percentage of Asthma-control Days Over the 6-month Treatment Period — 50.70; 53.30; 43.84 Percentage of days
Phase 3 N=1,441 A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related…
Phase 3 N=555 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Transfusional Iron Overload in β-thalassemia
Primary: Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event — 109; 113; 85; 110 Participants
Phase 3 N=94 Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
Kidney Diseases
Primary: Renal Function Assessed by Change in Estimated Glomerular Filtration Rate(eGFR) — 45.3; 56.4; 44.7; 49.1 mL/min/1.73m^2
Phase 3 N=111 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Macular Degeneration · Choroidal Neovascularization
Primary: Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline. — 59.4; 63.4; 71.1 Percentage of Participants
Phase 3 N=524 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
Infections, Papillomavirus
Primary: Anti-Human Papillomavirus (Anti-HPV)-16/18 Antibody Titers in Serum at Years 5, 6 and 7 — 1495.7; 518.7; 282.4; 1344.6 EL.U/mL
Phase 3 N=1,683 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants
Phase 3 N=22,439 Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
Shingles
Primary: Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group — 1.994; 6.596 number of HZ cases/1000 person-years — p=<.001
Phase 3 N=178 Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
Gastroesophageal Reflux
Primary: Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR. — 88 percent of…
Phase 3 N=62 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
Fungal Infection
Primary: Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment — 6; 32; 11; 10 Participants
Phase 3 N=57 Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
Hyponatremia
Primary: Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores) — 0.20; 0.39 Z-score — p=0.08